Jane Street Group LLC Boosts Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jane Street Group LLC raised its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 245.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 401,908 shares of the biopharmaceutical company’s stock after purchasing an additional 285,564 shares during the quarter. Jane Street Group LLC owned 0.34% of Catalyst Pharmaceuticals worth $7,990,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. GAMMA Investing LLC raised its holdings in Catalyst Pharmaceuticals by 62.1% in the third quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 681 shares during the period. nVerses Capital LLC acquired a new position in shares of Catalyst Pharmaceuticals during the 3rd quarter valued at $50,000. Larson Financial Group LLC boosted its position in Catalyst Pharmaceuticals by 27,218.2% during the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 2,994 shares during the period. CWM LLC increased its holdings in Catalyst Pharmaceuticals by 686.5% in the 2nd quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 3,549 shares in the last quarter. Finally, Meeder Asset Management Inc. purchased a new position in Catalyst Pharmaceuticals in the second quarter valued at about $70,000. 79.22% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CPRX has been the subject of a number of recent research reports. Truist Financial increased their target price on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, November 11th. Stephens initiated coverage on shares of Catalyst Pharmaceuticals in a research note on Monday, November 18th. They set an “overweight” rating and a $35.00 price objective on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, November 8th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Catalyst Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $31.14.

Catalyst Pharmaceuticals Stock Up 0.2 %

Shares of CPRX opened at $21.38 on Friday. The firm has a market cap of $2.55 billion, a price-to-earnings ratio of 18.12, a PEG ratio of 3.35 and a beta of 0.75. The business’s 50 day moving average is $21.62 and its two-hundred day moving average is $19.14. Catalyst Pharmaceuticals, Inc. has a 52-week low of $13.12 and a 52-week high of $24.27.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 12,000 shares of the firm’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total transaction of $272,640.00. Following the completion of the transaction, the insider now directly owns 51,391 shares of the company’s stock, valued at $1,167,603.52. This trade represents a 18.93 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Steve Miller sold 50,000 shares of the business’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the completion of the sale, the insider now directly owns 686,996 shares of the company’s stock, valued at $15,065,822.28. The trade was a 6.78 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 79,500 shares of company stock worth $1,754,140. Insiders own 11.00% of the company’s stock.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.